{
    "clinical_study": {
        "@rank": "11771", 
        "arm_group": [
            {
                "arm_group_label": "Ataluren (PTC124\u00ae)", 
                "arm_group_type": "Experimental", 
                "description": "Oral powder for suspension taken 3 times per day (10-, 10-, and 20-mg/kg morning, midday and evening, respectively) for 48 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo taken 3 times per day for 48 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled,\n      efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis\n      (nmCF) not receiving chronic inhaled aminoglycosides."
        }, 
        "brief_title": "Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Evidence of signed and dated informed consent/assent document(s) indicating that the\n             subject (and/or his parent/legal guardian) has been informed of all pertinent aspects\n             of the trial\n\n          -  Age >=6 years.\n\n          -  Body weight >=16 kg.\n\n          -  Sweat chloride >60 mEq/L\n\n          -  Documentation of the presence of a nonsense mutation in at least 1 allele of the CFTR\n             gene, as determined by genotyping performed at a laboratory certified by the College\n             of American Pathologists (CAP), or under the Clinical Laboratory Improvement\n             Act/Amendment (CLIA), or by an equivalent organization\n\n          -  Verification that a blood sample has been drawn for sequencing of the CFTR gene\n\n          -  Ability to perform a valid, reproducible spirometry test using the study-specific\n             spirometer with demonstration of an FEV1 >=40% and <=90% of predicted\n\n          -  Demonstration at Visit 2 of a valid %-predicted FEV1 within 15% of the Screening %\n             predicted FEV1 value\n\n          -  Resting oxygen saturation (as measured by pulse oximetry) >=92% on room air.\n\n          -  Confirmed screening laboratory values within pre-specified ranges\n\n          -  In subjects who are sexually active, willingness to abstain from sexual intercourse\n             or employ a barrier or medical method of contraception during the study drug\n             administration and 60-day follow-up period\n\n          -  Willingness and ability to comply with all study procedures and assessments,\n             including scheduled visits, drug administration plan, study procedures, laboratory\n             tests, and study restrictions\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to any of the ingredients or excipients of the study drug\n\n          -  Previous participation in the Phase 3 trial of ataluren (PTC124-GD-009-CF).\n\n          -  Any change (initiation, change in type of drug, dose modification, schedule\n             modification, interruption, discontinuation, or re-initiation) in a chronic\n             treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks\n             prior to screening\n\n          -  Chronic use of inhaled aminoglycosides (eg, tobramycin) or use of inhaled\n             aminoglycosides within 4 months prior to screening.\n\n          -  Exposure to another investigational drug within 4 weeks prior to screening\n\n          -  Ongoing participation in any other therapeutic clinical trial\n\n          -  Evidence of pulmonary exacerbation or acute upper or lower respiratory tract\n             infection (including viral illnesses) within 3 weeks prior to screening\n\n          -  Treatment with intravenous antibiotics within 3 weeks prior to screening\n\n          -  Ongoing immunosuppressive therapy (other than corticosteroids)\n\n          -  Ongoing warfarin, phenytoin, or tolbutamide therapy\n\n          -  History of solid organ or hematological transplantation\n\n          -  Major complications of lung disease (including massive hemoptysis, pneumothorax, or\n             pleural effusion) within 8 weeks prior to screening\n\n          -  Known portal hypertension\n\n          -  Positive hepatitis B surface antigen, hepatitis C antibody test, or human\n             immunodeficiency virus (HIV) test\n\n          -  Pregnancy or breast-feeding\n\n          -  Current smoker or a smoking history of >=10 pack-years (number of cigarette packs/day\n             x number of years smoked).\n\n          -  Prior or ongoing medical condition (eg, concomitant illness, alcoholism, drug abuse,\n             psychiatric condition), medical history, physical findings, ECG findings, or\n             laboratory abnormality that, in the investigator's opinion, could adversely affect\n             the safety of the subject, makes it unlikely that the course of treatment or\n             follow-up would be completed, or could impair the assessment of study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "208", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139306", 
            "org_study_id": "PTC124-GD-021-CF", 
            "secondary_id": "2013-004581-34"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ataluren (PTC124\u00ae)", 
                "intervention_name": "Ataluren (PTC124\u00ae)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "link": {
            "url": "http://www.ptcbio.com"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Heather Hathorne"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }, 
                "investigator": {
                    "last_name": "Steven Rowe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Candice Evans"
                }, 
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90806"
                    }, 
                    "name": "Miller Children's Hospital Long Beach"
                }, 
                "investigator": {
                    "last_name": "Terry W Chin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shelley Mann"
                }, 
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Children's Hospital Colorado"
                }, 
                "investigator": {
                    "last_name": "Frank Accurso, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Silvia Balladares-Huete"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33155"
                    }, 
                    "name": "Miami Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Maria E Franco, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Donna DiBenedetto"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10003"
                    }, 
                    "name": "Beth Israel Medical Center"
                }, 
                "investigator": {
                    "last_name": "Patricia A Walker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roberta Ksenich"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Rainbow Babies & Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Konstan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Efficacy and Safety Study of Ataluren (PTC124\u00ae) in Patients With Nonsense Mutation Cystic Fibrosis", 
        "other_outcome": [
            {
                "measure": "FVC and FEF25-75 by spirometry", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Incidence and duration of pulmonary exacerbations", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Other HRQL domains as assessed by the CFQ-R", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Concentrations of liver enzyme tests (AST, ALT, GGT)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Fecal calprotectin level", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "New Pseudomonas aeruginosa lung infection", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Safety profile characterized by type, frequency, severity, timing, and relationship to study drug of treatment-emergent adverse events, laboratory abnormalities, and ECG abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Study drug compliance as assessed by quantification of unused study drug", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Trough ataluren plasma concentrations", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "overall_contact": {
            "email": "dgoetz@ptcbio.com", 
            "last_name": "Diane Goetz", 
            "phone": "908-912-9256"
        }, 
        "overall_contact_backup": {
            "email": "patientinfo@ptcbio.com", 
            "last_name": "Diane Goetz", 
            "phone": "866-282-5873"
        }, 
        "overall_official": {
            "affiliation": "PTC Therapeutics", 
            "last_name": "Temitayo Ajayi, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Brazil: Ministry of Health", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Canada: Health Canada", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Israel: Israeli Health Ministry Pharmaceutical Administration", 
                "Italy: The Italian Medicines Agency", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "FEV1 by spirometry", 
            "safety_issue": "No", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of pulmonary exacerbations (modified Fuchs criteria)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Respiratory HRQL as assessed by the CFQ-R respiratory domain", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Body weight and BMI", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "PTC Therapeutics", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cystic Fibrosis Foundation Therapeutics-Therapeutics Development Network (CCFT-TDN)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "European Cystic Fibrosis Society-Clinical Trial Network (ECFS-CTN)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "PTC Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}